Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03369821 · ClinicalTrials.gov registry record
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
A clinical trial of Type1 Diabetes Mellitus, sponsored by University of Exeter.
- Recruiting
- Registry status
- 300
- Enrollment target
- 4
- Study locations
NCT03369821 is a study of Type1 Diabetes Mellitus that is actively recruiting participants, run by University of Exeter. The registered enrollment target is 300 participants, below the 709-participant average among 6 other Type1 Diabetes Mellitus trials with a reported enrollment target (58% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03369821, a study of Type1 Diabetes Mellitus, is actively recruiting participants, sponsored by University of Exeter.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 4
- Study locations
Study Summary
Type 1 diabetes (T1D) results from destruction of insulin-producing beta cells in the pancreas by the body's own immune system (autoimmunity). It is not fully understood what causes this type of diabetes and why there is variation in age of onset and severity between people who develop the disease. The aim of this work is to study very unusual people who develop T1D extremely young, as babies under 2 years of age (EET1D). The investigators think that, for the condition to have developed that early, they must have an unusual or extreme form of autoimmunity. Studying people with EET1D will enable us to look at exactly what goes wrong with the immune system because they have one of the most extreme forms of the disease. Much may be learned about the disease from a small number of rare individuals. The investigators aim to confirm that they have autoimmune type 1 diabetes and then try to understand how they have developed diabetes so young by studying their immune system genes, the function of their immune system, and environmental factors (such as maternal genetics) that may play a role in their development of the disease. People with diabetes diagnosed under 12 months are very rare, live all over the world. and are usually referred to Exeter for genetic testing. Individuals will be contacted via their clinician to ask for more information about their diabetes and their family history. Samples will be collected to study whether they still make any of their own insulin and whether they make specific antibodies against their beta cells in the pancreas. Separately, their immune system will be studied in depth using immune cells isolated from a blood sample. These cells will undergo cutting edge techniques by Dr Tim Tree at King's College London, by Professor Bart Roep at Leiden University Medical Center, Netherlands, and Dr Cate Speake, Benaroya Research Institute, Seattle (USA). Some of these tests have never been used in people of young ages around the world, so an ai
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Beta Cell Loss and Immune Function
- OTHER Immune Function with RNAseq
Study Locations (4)
Washington
- Benaroya Research Institute - Seattle
Leiden
- Leiden University Medical Center - Leiden
Devon
- Royal Devon & Exeter NHS Foundation Trust - Exeter
Other
- King's College London - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2028-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03369821
The ClinicalTrials.gov registry entry for NCT03369821 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 709-participant average among 6 other Type1 Diabetes Mellitus trials with a reported enrollment target (58% lower). The listed sponsor is University of Exeter, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Beta Cell Loss and Immune Function is the first listed.
NCT03369821 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Washington, Leiden, Devon.
Frequently Asked Questions
What is clinical trial NCT03369821 about?
NCT03369821 is a clinical study titled "EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)". Type 1 diabetes (T1D) results from destruction of insulin-producing beta cells in the pancreas by the body's own immune system (autoimmunity). It is not fully understood what causes this type of diabetes and why there is variation in age of onset and severity between people who develop the disease. ...
What is the current status of trial NCT03369821?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2017-09-19. Estimated completion is 2028-11-30.
What conditions does trial NCT03369821 study?
This clinical trial studies the following conditions: Type1 Diabetes Mellitus.
What interventions are being tested in trial NCT03369821?
The interventions under investigation include: Beta Cell Loss and Immune Function (DIAGNOSTIC_TEST), Immune Function with RNAseq (OTHER).
Who is sponsoring clinical trial NCT03369821?
This trial is sponsored by University of Exeter, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03369821 being conducted?
This trial has 4 study locations across Washington, Leiden, Devon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
ACTIVE NOT RECRUITING
-
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
COMPLETED · Phase 2
-
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
COMPLETED · Phase 1
-
The Insulin-Only Bionic Pancreas Bridging Study
COMPLETED · Phase 2
-
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.